Publications by authors named "Manami Kamishima"
Background: An observational post-marketing surveillance (PMS) is being conducted to evaluate the long-term safety and effectiveness of bedaquiline as part of combination therapies in treating pulmonary multidrug-resistant tuberculosis (MDR-TB) in Japan.
Methods: This interim analysis includes patients with MDR-TB who started bedaquiline-containing anti-tuberculosis (TB) drugs in Japan between January 2018 and September 2022. Outcomes include the incidence of adverse drug reactions (ADRs) and negative sputum cultures.
Article Synopsis
- A 52-week study assessed the safety and effectiveness of guselkumab, a monoclonal antibody used to treat various forms of psoriasis in Japanese patients, with reported results from a 20-week interim analysis.
- Out of 411 patients analyzed for safety, 6.6% experienced adverse drug reactions (ADRs), with the most common being infections, while 2.2% had serious ADRs.
- Improvements in psoriasis severity were significant, with scores dropping from 11.6 at baseline to 2.2 by week 20, highlighting guselkumab's tolerability and effectiveness in real-world settings.
Exposure to endocrine-disrupting chemicals may adversely affect animals, particularly during development. Tris(1,3-dichloroisopropyl) phosphate (TDCIPP) is an organophosphate with anti-androgen function in vitro that is present in indoor dust at relatively high concentrations. In male rats, androgens are necessary for the development of reproductive organs, as well as the endocrine and central nervous systems.
View Article and Find Full Text PDF